[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"company-c-134":3},{"queryId":4,"companyId":5,"companySlug":6,"companyName":7,"summary":8,"tags":9,"keyData":10,"markdownContent":11,"lifecycleStage":12,"sections":13,"sources":61,"status":17,"updatedAt":103},"2037096866365284354","2037097423247220737","c-134","Allergan Aesthetics, LLC (美国); 艾尔建美学（上海）商贸有限公司 (中国)","Allergan Aesthetics 是艾伯维（AbbVie）旗下专注于医疗美容领域的全球领导者，是一家全资子公司。其前身是艾尔建（Allergan plc）的美学业务部门，在艾伯维于2020年完成收购后，作为独立品牌和运营实体整合至艾伯维集团内，直接向艾伯维执行委员会汇报。","[\"Allergan Aesthetics, LLC (美国); 艾尔建美学（上海）商贸有限公司 (中国)\",\"成熟期\"]","{\"email\": \"info@allerganaesthetics.com\", \"phone\": \"+1-800-678-1605 (美国医学信息)\", \"address\": \"2525 Dupont Drive, Irvine, CA 92612, USA (全球总部)；中国办公室：上海市静安区南京西路1266号恒隆广场2期2801单元\", \"revenue\": \"2025年净收入32亿美元\", \"website\": \"https:\u002F\u002Fwww.allerganaesthetics.com\u002F\", \"legal_name\": \"Allergan Aesthetics, LLC (美国); 艾尔建美学（上海）商贸有限公司 (中国)\", \"duns_number\": \"信息不足\", \"founded_year\": \"作为独立运营实体的有效起始年份为2020年（艾伯维收购完成后）\", \"headquarters\": \"美国加利福尼亚州尔湾市\", \"listing_info\": \"未独立上市，为艾伯维（NYSE: ABBV）全资子公司\", \"core_business\": \"开发、制造和销售面部注射类医疗美容产品（如肉毒毒素、透明质酸填充剂）的全球领导者\", \"target_market\": \"全球市场（覆盖100多个国家）\", \"employee_count\": \"约4200名专业人员\", \"identity_number\": \"91310000MA1FPXQJ3F (中国子公司统一社会信用代码)\"}","# Allergan Aesthetics, LLC (美国); 艾尔建美学（上海）商贸有限公司 (中国)\n\n## 1. 核心身份标签\n\nAllergan Aesthetics 是艾伯维（AbbVie）旗下专注于医疗美容领域的全球领导者，是一家全资子公司。其前身是艾尔建（Allergan plc）的美学业务部门，在艾伯维于2020年完成收购后，作为独立品牌和运营实体整合至艾伯维集团内，直接向艾伯维执行委员会汇报。\n\n## 2. 战略愿景与使命\n\n搜索结果中未明确提及公司的具体愿景或使命声明。然而，从公司行为可推断其战略核心是成为全球医疗美容领域的创新领导者，致力于通过提供全面的产品组合、以患者为中心的个性化治疗方案（AA Signature™框架）以及持续的临床医生教育（AA Academy平台），推动行业标准并满足全球消费者对自然、个性化美学效果日益增长的需求。\n\n## 3. 业务架构与产品矩阵\n\n公司业务覆盖超过100个国家，在全球主要市场（如美国、欧洲、日本、中国）设有法律实体和运营机构。其核心业务是开发、制造和销售面部注射类医疗美容产品。\n**核心产品矩阵**：\n1.  **肉毒毒素产品**：\n    *   **BOTOX® Cosmetic (onabotulinumtoxinA)**：核心旗舰产品，用于改善面部皱纹。\n    *   **trenibotulinumtoxinE**：新近获批的首创E型肉毒神经毒素，据称起效更快（24小时内），效果可持续长达6个月。\n2.  **透明质酸填充剂产品**：\n    *   **JUVÉDERM® 系列**：包括 JUVÉDERM VOLUMA® XC（用于面部塑形）、JUVÉDERM ULTRA® XC（用于唇部填充）等。\n    *   **JUVÉDERM VOLUX® XC+**：下一代透明质酸填充剂，预计于2026-2027年在欧美上市。\n3.  **其他产品**：\n    *   **LATISSE®**：用于促进睫毛生长的产品。\n    *   公司在中国市场获得了包括上述产品在内的共14款产品的国家药监局（NMPA）批准。\n\n## 4. 核心能力与护城河\n\n1.  **强大的产品组合与研发管线**：拥有全球知名的BOTOX®和JUVÉDERM®品牌，并持续推出创新产品（如trenibotulinumtoxinE、VOLUX® XC+），研发投入巨大（2025年达4.2亿美元）。\n2.  **全球化的商业与监管运营**：在100多个国家开展业务，具备应对FDA、EMA、NMPA、PMDA等主要监管机构的丰富经验。\n3.  **以临床医生为中心的教育体系**：通过官方、受认证的AA Academy平台提供多语言继续医学教育（CME\u002FCE），构建了强大的专业社群和品牌忠诚度。\n4.  **数据驱动的临床与市场洞察**：进行大规模全球患者研究（如覆盖18国、超1.2万患者的2025-2026研究），并在顶级学术会议（如IMCAS、ASDS、AMWC）上持续发布临床数据，支持产品有效性和安全性。\n5.  **艾伯维集团的资源支持**：作为艾伯维四大核心治疗领域之一，享有母公司在财务、研发和全球基础设施方面的支持。\n\n## 5. 目标市场与客户\n\n*   **目标市场**：全球市场，重点覆盖北美、欧洲、亚太（包括中国、日本）等主要医疗美容市场。\n*   **直接客户**：持有相关资质的医疗美容临床医生（如皮肤科医生、整形外科医生、美容医师）。\n*   **终端用户**：寻求医疗美容治疗的消费者。研究显示，其需求趋势包括追求自然效果（89%）、偏好个性化治疗方案（94%）以及对联合治疗兴趣增加。\n\n## 6. 品牌形象与价值观\n\n品牌形象定位为科学、专业、创新的全球医疗美容权威。通过积极参与顶级行业学术会议、发布大量临床研究数据、提供严谨的临床医生教育，强化其“科学引领美学”的专业形象。其AA Signature™框架强调“以患者为中心”和“多模式治疗”的价值观。在传播上，主要通过专业渠道（如LinkedIn、学术会议）与医疗专业人士沟通，而非直接面向消费者营销。\n\n## 7. 发展生命周期\n\n公司目前处于**成熟期并持续创新**。作为被收购后整合进更大集团的业务单元，它依托成熟的品牌和全球渠道保持稳定增长（2025年营收增长7.3%）。同时，通过持续推出新产品（如新型肉毒毒素、下一代填充剂）、整合数字健康工具（如AI治疗规划）和拓展教育平台，不断寻求新的增长点，以应对市场竞争和消费者需求变化。\n\n## 8. 潜在挑战与风险\n\n1.  **市场竞争**：全球及区域医疗美容市场竞争激烈，面临来自其他国际药企及本土公司的产品竞争。\n2.  **监管风险**：产品属于严格监管的医疗器械和药品，在全球各市场的注册、审批、上市后监管要求复杂且可能变化。\n3.  **产品集中风险**：营收高度依赖BOTOX® Cosmetic和JUVÉDERM®等核心产品，需要持续创新以维持市场地位。\n4.  **合规与安全**：产品使用依赖于临床医生的操作，不当使用可能引发安全性问题，需持续投入医生培训和不良反应监测。\n\n## 9. 综述\n\nAllergan Aesthetics 是艾伯维集团内一个定位清晰、运营独立的全球医疗美容巨头。它成功地将强大的品牌资产（BOTOX®, JUVÉDERM®）、持续的产品创新、深厚的临床学术支持和全球化的商业能力相结合，构建了坚实的竞争壁垒。公司不仅销售产品，更通过AA Academy和AA Signature™框架塑造行业治疗标准和教育生态，致力于与医疗专业人士共同推动医疗美容领域的专业化发展。未来，其在数字健康工具和新产品管线上的投入，将是维持其领导地位的关键。\n\n## 结构化关键数据\n\n\u003C!--KEY_DATA-->\n{\"email\": \"info@allerganaesthetics.com\", \"phone\": \"+1-800-678-1605 (美国医学信息)\", \"address\": \"2525 Dupont Drive, Irvine, CA 92612, USA (全球总部)；中国办公室：上海市静安区南京西路1266号恒隆广场2期2801单元\", \"revenue\": \"2025年净收入32亿美元\", \"website\": \"https:\u002F\u002Fwww.allerganaesthetics.com\u002F\", \"legal_name\": \"Allergan Aesthetics, LLC (美国); 艾尔建美学（上海）商贸有限公司 (中国)\", \"duns_number\": \"信息不足\", \"founded_year\": \"作为独立运营实体的有效起始年份为2020年（艾伯维收购完成后）\", \"headquarters\": \"美国加利福尼亚州尔湾市\", \"listing_info\": \"未独立上市，为艾伯维（NYSE: ABBV）全资子公司\", \"core_business\": \"开发、制造和销售面部注射类医疗美容产品（如肉毒毒素、透明质酸填充剂）的全球领导者\", \"target_market\": \"全球市场（覆盖100多个国家）\", \"employee_count\": \"约4200名专业人员\", \"identity_number\": \"91310000MA1FPXQJ3F (中国子公司统一社会信用代码)\"}","成熟期",[14,21,26,31,36,41,46,51,56],{"id":15,"profileId":16,"sectionNo":17,"sectionName":18,"content":8,"sortOrder":17,"identityId":19,"createdAt":20},2037097419099054000,2037097418914504700,1,"核心身份标签",null,"2026-03-26T09:20:47.000+00:00",{"id":22,"profileId":16,"sectionNo":23,"sectionName":24,"content":25,"sortOrder":23,"identityId":19,"createdAt":20},2037097419287797800,2,"战略愿景与使命","搜索结果中未明确提及公司的具体愿景或使命声明。然而，从公司行为可推断其战略核心是成为全球医疗美容领域的创新领导者，致力于通过提供全面的产品组合、以患者为中心的个性化治疗方案（AA Signature™框架）以及持续的临床医生教育（AA Academy平台），推动行业标准并满足全球消费者对自然、个性化美学效果日益增长的需求。",{"id":27,"profileId":16,"sectionNo":28,"sectionName":29,"content":30,"sortOrder":28,"identityId":19,"createdAt":20},2037097419476541400,3,"业务架构与产品矩阵","公司业务覆盖超过100个国家，在全球主要市场（如美国、欧洲、日本、中国）设有法律实体和运营机构。其核心业务是开发、制造和销售面部注射类医疗美容产品。\n**核心产品矩阵**：\n1.  **肉毒毒素产品**：\n    *   **BOTOX® Cosmetic (onabotulinumtoxinA)**：核心旗舰产品，用于改善面部皱纹。\n    *   **trenibotulinumtoxinE**：新近获批的首创E型肉毒神经毒素，据称起效更快（24小时内），效果可持续长达6个月。\n2.  **透明质酸填充剂产品**：\n    *   **JUVÉDERM® 系列**：包括 JUVÉDERM VOLUMA® XC（用于面部塑形）、JUVÉDERM ULTRA® XC（用于唇部填充）等。\n    *   **JUVÉDERM VOLUX® XC+**：下一代透明质酸填充剂，预计于2026-2027年在欧美上市。\n3.  **其他产品**：\n    *   **LATISSE®**：用于促进睫毛生长的产品。\n    *   公司在中国市场获得了包括上述产品在内的共14款产品的国家药监局（NMPA）批准。",{"id":32,"profileId":16,"sectionNo":33,"sectionName":34,"content":35,"sortOrder":33,"identityId":19,"createdAt":20},2037097419661090800,4,"核心能力与护城河","1.  **强大的产品组合与研发管线**：拥有全球知名的BOTOX®和JUVÉDERM®品牌，并持续推出创新产品（如trenibotulinumtoxinE、VOLUX® XC+），研发投入巨大（2025年达4.2亿美元）。\n2.  **全球化的商业与监管运营**：在100多个国家开展业务，具备应对FDA、EMA、NMPA、PMDA等主要监管机构的丰富经验。\n3.  **以临床医生为中心的教育体系**：通过官方、受认证的AA Academy平台提供多语言继续医学教育（CME\u002FCE），构建了强大的专业社群和品牌忠诚度。\n4.  **数据驱动的临床与市场洞察**：进行大规模全球患者研究（如覆盖18国、超1.2万患者的2025-2026研究），并在顶级学术会议（如IMCAS、ASDS、AMWC）上持续发布临床数据，支持产品有效性和安全性。\n5.  **艾伯维集团的资源支持**：作为艾伯维四大核心治疗领域之一，享有母公司在财务、研发和全球基础设施方面的支持。",{"id":37,"profileId":16,"sectionNo":38,"sectionName":39,"content":40,"sortOrder":38,"identityId":19,"createdAt":20},2037097419849834500,5,"目标市场与客户","*   **目标市场**：全球市场，重点覆盖北美、欧洲、亚太（包括中国、日本）等主要医疗美容市场。\n*   **直接客户**：持有相关资质的医疗美容临床医生（如皮肤科医生、整形外科医生、美容医师）。\n*   **终端用户**：寻求医疗美容治疗的消费者。研究显示，其需求趋势包括追求自然效果（89%）、偏好个性化治疗方案（94%）以及对联合治疗兴趣增加。",{"id":42,"profileId":16,"sectionNo":43,"sectionName":44,"content":45,"sortOrder":43,"identityId":19,"createdAt":20},2037097420034384000,6,"品牌形象与价值观","品牌形象定位为科学、专业、创新的全球医疗美容权威。通过积极参与顶级行业学术会议、发布大量临床研究数据、提供严谨的临床医生教育，强化其“科学引领美学”的专业形象。其AA Signature™框架强调“以患者为中心”和“多模式治疗”的价值观。在传播上，主要通过专业渠道（如LinkedIn、学术会议）与医疗专业人士沟通，而非直接面向消费者营销。",{"id":47,"profileId":16,"sectionNo":48,"sectionName":49,"content":50,"sortOrder":48,"identityId":19,"createdAt":20},2037097420223127600,7,"发展生命周期","公司目前处于**成熟期并持续创新**。作为被收购后整合进更大集团的业务单元，它依托成熟的品牌和全球渠道保持稳定增长（2025年营收增长7.3%）。同时，通过持续推出新产品（如新型肉毒毒素、下一代填充剂）、整合数字健康工具（如AI治疗规划）和拓展教育平台，不断寻求新的增长点，以应对市场竞争和消费者需求变化。",{"id":52,"profileId":16,"sectionNo":53,"sectionName":54,"content":55,"sortOrder":53,"identityId":19,"createdAt":20},2037097420411871200,8,"潜在挑战与风险","1.  **市场竞争**：全球及区域医疗美容市场竞争激烈，面临来自其他国际药企及本土公司的产品竞争。\n2.  **监管风险**：产品属于严格监管的医疗器械和药品，在全球各市场的注册、审批、上市后监管要求复杂且可能变化。\n3.  **产品集中风险**：营收高度依赖BOTOX® Cosmetic和JUVÉDERM®等核心产品，需要持续创新以维持市场地位。\n4.  **合规与安全**：产品使用依赖于临床医生的操作，不当使用可能引发安全性问题，需持续投入医生培训和不良反应监测。",{"id":57,"profileId":16,"sectionNo":58,"sectionName":59,"content":60,"sortOrder":58,"identityId":19,"createdAt":20},2037097420609003500,9,"综述","Allergan Aesthetics 是艾伯维集团内一个定位清晰、运营独立的全球医疗美容巨头。它成功地将强大的品牌资产（BOTOX®, JUVÉDERM®）、持续的产品创新、深厚的临床学术支持和全球化的商业能力相结合，构建了坚实的竞争壁垒。公司不仅销售产品，更通过AA Academy和AA Signature™框架塑造行业治疗标准和教育生态，致力于与医疗专业人士共同推动医疗美容领域的专业化发展。未来，其在数字健康工具和新产品管线上的投入，将是维持其领导地位的关键。",[62,67,72,78,83,88,93,98,104,109,114,119,124],{"id":63,"profileId":16,"sectionNo":17,"title":64,"url":65,"sourceType":17,"publishTime":19,"credibility":38,"snippet":66,"createdAt":20},2037097420797747200,"Allergan Aesthetics, an AbbVie Company: Global Leader in Medical Aesthetics","https:\u002F\u002Fwww.allerganaesthetics.com\u002F","Allergan Aesthetics is a global medical aesthetics company and a wholly owned subsidiary of AbbVie (NYSE: ABBV). It develops, manufactures, and markets a comprehensive portfolio of facial injectables—including BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® family of hyaluronic acid fillers, and the newly approved trenibotulinumtoxinE (first-in-class botulinum neurotoxin serotype E). The company operates across 100+ countries, with R&D hubs in Irvine (CA), Paris, and London. Its AA Signature™ framework guides multimodal, patient-centric treatment approaches. Contact: +1-800-678-1605 (US), info@allerganaesthetics.com.",{"id":68,"profileId":16,"sectionNo":23,"title":69,"url":70,"sourceType":17,"publishTime":19,"credibility":38,"snippet":71,"createdAt":20},2037097420986491000,"Allergan Aesthetics Announces New Global Consumer Research at AMWC 2026","https:\u002F\u002Fwww.allerganaesthetics.com\u002Fnews\u002Fpress-releases\u002Fallergan-aesthetics-announces-new-global-consumer-research-at-amwc-2026","At the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco, Allergan Aesthetics unveiled findings from its 2025–2026 Global Patient Expectations Study—surveying over 12,000 patients across 18 countries. Key insights include rising demand for natural-looking outcomes (89%), preference for personalized treatment plans (94%), and increased interest in combination therapies (e.g., toxin + filler + skin health). The company launched the enhanced AA Signature™ 3.0 framework, integrating AI-powered treatment mapping tools and clinician training modules available via AA Academy online platform.",{"id":73,"profileId":16,"sectionNo":28,"title":74,"url":75,"sourceType":76,"publishTime":19,"credibility":38,"snippet":77,"createdAt":20},2037097421171040300,"Allergan Aesthetics China Subsidiary Registered with SAMR","https:\u002F\u002Fwww.gsxt.gov.cn\u002Fcorp-query-homepage.html?keyword=艾尔建美学",0,"Allergan Aesthetics (Shanghai) Trading Co., Ltd. (艾尔建美学（上海）商贸有限公司) registered with China’s State Administration for Market Regulation (SAMR) on June 15, 2021. Unified Social Credit Code: 91310000MA1FPXQJ3F. Registered capital: ¥100 million RMB. Legal representative: Zhang Wei. Business scope includes import\u002Fexport of medical aesthetics devices and drugs, technical consulting, and training. Approved by NMPA for 14 products including BOTOX® Cosmetic (NMPA License No. S20200012), JUVÉDERM® VOLUMA® XC (S20210045), and LATISSE® (S20220089). Office: Unit 2801, Plaza 66 Tower II, Shanghai.",{"id":79,"profileId":16,"sectionNo":33,"title":80,"url":81,"sourceType":76,"publishTime":19,"credibility":38,"snippet":82,"createdAt":20},2037097421359784000,"Allergan Aesthetics – Business Registration & Legal Entity Details (U.S.)","https:\u002F\u002Fbusiness-search.sos.ca.gov\u002Fcovid\u002Fbusiness-search?name=Allergan+Aesthetics","Registered as 'Allergan Aesthetics, LLC' in California (File No. C4278920), effective October 1, 2020. Parent entity: AbbVie Inc. (DE File No. 5717793). Principal address: 2525 Dupont Drive, Irvine, CA 92612. Registered agent: Corporation Service Company. Status: Active. NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing). Employer Identification Number (EIN): 84-4203241. Authorized to transact business in all 50 U.S. states and Puerto Rico. Foreign qualification filings confirmed in UK (Companies House: 12478192), France (RCS Paris: 882 231 512), and Japan (Tokyo Legal Affairs Bureau: 0100-01-24789).",{"id":84,"profileId":16,"sectionNo":38,"title":85,"url":86,"sourceType":17,"publishTime":19,"credibility":38,"snippet":87,"createdAt":20},2037097421548527600,"Allergan Aesthetics Global Medical Information Contacts","https:\u002F\u002Fwww.allerganaesthetics.com\u002Fmedical-information\u002Fglobal-contacts","Official Medical Information (MI) contacts per region: US — 1-800-678-1605, mi.us@abbvie.com; Canada — 1-800-263-8337, mi.ca@abbvie.com; EU — +31 20 566 9111, mi.eu@abbvie.com; Japan — 0120-111-400, mi.jp@abbvie.com; Australia — 1800 803 403, mi.au@abbvie.com. All lines staffed Monday–Friday, 8:30am–5:30pm local time. MI responses issued within 2 business days; adverse event reporting available 24\u002F7 via www.abbvie.com\u002Fsafety. Product labeling and PI documents accessible in 32 languages on the Allergan Aesthetics Document Library portal.",{"id":89,"profileId":16,"sectionNo":43,"title":90,"url":91,"sourceType":17,"publishTime":19,"credibility":38,"snippet":92,"createdAt":20},2037097421733077000,"Allergan Aesthetics – Corporate Profile | AbbVie Investor Relations","https:\u002F\u002Finvestor.abbvie.com\u002Fcorporate-profile\u002Ftherapeutic-areas\u002Faesthetics","AbbVie’s official investor relations page confirms Allergan Aesthetics as one of its four core therapeutic pillars (alongside immunology, oncology, and neuroscience). The division generated $3.2B in net revenue in 2025 (up 7.3% YoY), representing ~14% of AbbVie’s total revenue. Key brands: BOTOX® Cosmetic ($1.8B), JUVÉDERM® ($1.1B), and LATISSE® ($280M). R&D investment totaled $420M in 2025, focused on novel toxins, next-gen HA fillers, and digital health integration. Headquarters: Irvine, California, USA. Global HQ office: 2525 Dupont Drive, Irvine, CA 92612.",{"id":94,"profileId":16,"sectionNo":48,"title":95,"url":96,"sourceType":23,"publishTime":19,"credibility":38,"snippet":97,"createdAt":20},2037097421921820700,"Allergan Aesthetics Presents New Data at IMCAS World Congress 2026 in Paris","https:\u002F\u002Fimcas.com\u002Fen\u002Fpress-releases\u002Fallergan-aesthetics-presents-new-data-at-imcas-2026","At IMCAS World Congress (Jan 29–31, 2026, Paris), Allergan Aesthetics presented 14 e-posters and hosted 3 symposia. Highlights included 12-month durability data for JUVÉDERM VOLUMA® XC, real-world safety profile of BOTOX® Cosmetic in Asian populations (n=4,217), and Phase 3 results for trenibotulinumtoxinE showing onset within 24h and duration up to 6 months. The company also previewed its next-gen HA filler JUVÉDERM VOLUX® XC+, expected to launch in EU Q3 2026 and US Q1 2027. Regulatory submissions filed with EMA and FDA.",{"id":99,"profileId":16,"sectionNo":53,"title":100,"url":101,"sourceType":17,"publishTime":19,"credibility":38,"snippet":102,"createdAt":103},2037097422110564400,"Allergan Aesthetics Launches AA Academy: Global Clinician Education Platform","https:\u002F\u002Facademy.allerganaesthetics.com\u002F","AA Academy is Allergan Aesthetics’ official, ACCME-accredited clinician education platform offering CME\u002FCE credits across 42 countries. Features include on-demand modules (e.g., 'Multimodal Facial Rejuvenation', 'Ethnic-Specific Injection Techniques'), live webinars with KOLs, case-based assessments, and AI-assisted injection simulation tools. Free registration required; content available in English, Spanish, French, German, Japanese, Mandarin, and Arabic. Platform integrates with credentialing systems of ASPS, ISAPS, and EADV. Technical support: academy.support@abbvie.com; phone: +1-844-222-2336.","2026-03-26T09:20:48.000+00:00",{"id":105,"profileId":16,"sectionNo":58,"title":106,"url":107,"sourceType":23,"publishTime":19,"credibility":38,"snippet":108,"createdAt":103},2037097422295113700,"Allergan Aesthetics at ASDS Annual Meeting 2025: 17 Abstracts Highlight Innovation","https:\u002F\u002Fwww.asds.net\u002FNews\u002FPress-Releases\u002F2025\u002FAllergan-Aesthetics-Presents-17-Abstracts-at-ASDS-2025","At the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting (Chicago, Nov 12–16), Allergan Aesthetics presented 17 peer-reviewed abstracts—including three in the prestigious 'Cosmetic Top Ten' session. Notable data: 4-phase study confirming high patient satisfaction (92% 'very satisfied') with 64U BOTOX® for upper facial lines across diverse ethnicities; real-world effectiveness of JUVÉDERM ULTRA® XC in lip augmentation; and safety outcomes of off-label use patterns tracked via Allergan Aesthetics’ Global Registry (N > 85,000 procedures). No direct sales contact provided; all product inquiries directed to www.allerganaesthetics.com\u002Fcontact.",{"id":110,"profileId":16,"sectionNo":17,"title":111,"url":112,"sourceType":23,"publishTime":19,"credibility":38,"snippet":113,"createdAt":103},2037097422483857400,"AbbVie Completes Acquisition of Allergan; Creates Global Leader in Medical Aesthetics","https:\u002F\u002Fnews.abbvie.com\u002Fnews-releases\u002Fnews-release-details\u002Fabbvie-completes-acquisition-allergan-creates-global-leader","AbbVie (NYSE: ABBV) officially completed its $63 billion acquisition of Allergan plc on May 8, 2020. Post-integration, Allergan Aesthetics became AbbVie’s dedicated medical aesthetics division, retaining its brand identity and commercial infrastructure. The transaction expanded AbbVie’s presence in dermatology, ophthalmology, and aesthetics. Allergan Aesthetics now reports directly to AbbVie’s Executive Committee and maintains separate regulatory, clinical, and marketing operations for aesthetic products under FDA, EMA, and PMDA oversight.",{"id":115,"profileId":16,"sectionNo":23,"title":116,"url":117,"sourceType":33,"publishTime":19,"credibility":33,"snippet":118,"createdAt":103},2037097422680989700,"Allergan Aesthetics on LinkedIn: Official Company Page","https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fallergan-aesthetics\u002F","Allergan Aesthetics’ verified LinkedIn page (127K followers) serves as its primary professional social channel. Updated daily with clinical updates, event highlights (e.g., AMWC 2026 recap videos), and clinician spotlights. Posts link to peer-reviewed publications, AA Academy registration, and regional medical affairs contacts (e.g., US: aesthetics.medaffairs@abbvie.com; EU: eu.aesthetics.medinfo@abbvie.com). No direct sales or patient support—redirects to www.allerganaesthetics.com\u002Fhelp. Privacy policy and GDPR compliance statements published in bio section.",{"id":120,"profileId":16,"sectionNo":28,"title":121,"url":122,"sourceType":76,"publishTime":19,"credibility":33,"snippet":123,"createdAt":103},2037097422869733400,"Allergan Aesthetics Careers – Global Employment Opportunities","https:\u002F\u002Fcareers.allerganaesthetics.com\u002F","Allergan Aesthetics employs ~4,200 professionals worldwide, with major offices in Irvine (CA), Paris, London, Tokyo, Singapore, São Paulo, and Dubai. Open roles include Clinical Science Managers, Medical Affairs Directors, Regulatory Affairs Specialists (FDA\u002FEMA\u002FPMDA), and Digital Health Product Leads. All positions require affiliation with AbbVie’s global compliance and ethics program. Benefits include access to AA Academy CE credits, product training, and cross-functional rotation programs. Application portal accessible exclusively via careers.allerganaesthetics.com; no third-party recruiters accepted without prior written authorization from AbbVie Talent Acquisition.",{"id":125,"profileId":16,"sectionNo":33,"title":126,"url":127,"sourceType":76,"publishTime":19,"credibility":33,"snippet":128,"createdAt":103},2037097423054282800,"Allergan Aesthetics – Wikipedia Entry (Last Edited March 2026)","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FAllergan_Aesthetics","Wikipedia entry confirms Allergan Aesthetics’ origin as the aesthetics division spun out from Allergan plc post-AbbVie acquisition. Describes key products (BOTOX®, JUVÉDERM®, LATISSE®, VOLUMA®, VOLIFT®, VOLBELLA®), clinical trial milestones (including FDA approval of trenibotulinumtoxinE in December 2025), and corporate governance structure. Notes that while branded independently, it has no separate board—reporting to AbbVie’s Chief Scientific Officer and Chief Commercial Officer. References FDA Orange Book, EMA EPARs, and annual AbbVie SEC 10-K filings as authoritative sources. Contains citation links to primary regulatory documents."]